【24h】

Refractory response to platelet transfusion therapy.

机译:对血小板输注治疗的难治性反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Platelet transfusions are commonly used for prophylaxis and treatment of bleeding. After a transfusion, an increment or "boost" is expected to occur. While a number of factors can contribute to a poor posttransfusion increment, refractoriness is typically defined as failure to achieve an appropriate increment after receiving 2 consecutive transfusions with fresh ABO-compatible platelets. The most common cause of refractoriness is contamination of the platelet product with leukocytes, resulting in human leukocyte antigens antibody formation. ABO incompatibility and human platelet antigens are also implicated in the development of refractoriness. Nurses who infuse platelets must understand these causes to assist in prevention and management.
机译:血小板输注通常用于预防和治疗出血。输血后,预计会发生增加或“升压”。尽管许多因素可能导致输血后增量增加,但难治性通常定义为连续两次输注新鲜ABO相容性血小板后未能达到适当的增量。最难治的原因是血小板产物被白细胞污染,导致人白细胞抗原抗体形成。 ABO不相容性和人血小板抗原也与难治性发展有关。灌注血小板的护士必须了解这些原因,以帮助预防和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号